SELLAS Life Sciences Group 향후 성장

Future 기준 점검 5/6

SELLAS Life Sciences Group은 연간 수입과 매출이 각각 63.5%와 67.2% 증가할 것으로 예상되고 EPS는 연간 64.5%만큼 증가할 것으로 예상됩니다.

핵심 정보

63.5%

이익 성장률

64.45%

EPS 성장률

Biotechs 이익 성장	25.1%
매출 성장률	67.2%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	13 May 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Jun 30

Why Sellas Remains A Strong Sell After Doubling In Price

Summary Sellas Life Sciences has nearly doubled in value, yet fundamentals remain unchanged and do not justify its $2.5B–$3B valuation. The REGAL trial is a high-risk, binary event with a challenging efficacy bar, and delayed events likely reflect stronger control arm performance, not GPS benefit. Even with REGAL success, the AML CR2 market opportunity is niche, making SLS overvalued even on optimistic risk-adjusted NPV assumptions. I maintain a Strong Sell rating on SLS due to asymmetric risk: I think downside on failure is severe, while upside on success is already priced in. Read the full article on Seeking Alpha

분석 기사 • Jun 17

SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing

Why the new shelf registration matters for SELLAS Life Sciences Group stock SELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common shares, an event that puts potential future capital raising firmly on investors’ radar. The filing follows recent shareholder meetings that backed board proposals and an expanded equity plan. This development sets the stage for possible use of this shelf as SELLAS funds its late stage oncology programs and...

분석 기사 • Oct 08

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Jun 25

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

분석 기사 • Nov 23

이익 및 매출 성장 예측

NasdaqCM:SLS - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	102	-8	N/A	N/A	1
12/31/2027	44	-27	N/A	N/A	1
12/31/2026	N/A	-37	N/A	N/A	1
3/31/2026	N/A	-29	-28	-28	N/A
12/31/2025	N/A	-27	-28	-28	N/A
9/30/2025	N/A	-26	-31	-31	N/A
6/30/2025	N/A	-26	-31	-31	N/A
3/31/2025	N/A	-27	-34	-34	N/A
12/31/2024	N/A	-31	-35	-35	N/A
9/30/2024	N/A	-32	-33	-33	N/A
6/30/2024	N/A	-34	-35	-32	N/A
3/31/2024	N/A	-36	-36	-30	N/A
12/31/2023	N/A	-37	-37	-31	N/A
9/30/2023	N/A	-38	-37	-32	N/A
6/30/2023	N/A	-36	-33	-31	N/A
3/31/2023	N/A	-36	-33	-29	N/A
12/31/2022	1	-41	-28	-24	N/A
9/30/2022	1	-39	-28	-24	N/A
6/30/2022	1	-39	-28	-24	N/A
3/31/2022	3	-35	-23	-23	N/A
12/31/2021	8	-21	-26	-26	N/A
9/30/2021	10	-18	-18	-18	N/A
6/30/2021	10	-15	-15	-15	N/A
3/31/2021	8	-15	-14	-14	N/A
12/31/2020	2	-17	-10	-10	N/A
9/30/2020	N/A	-21	-18	-18	N/A
6/30/2020	N/A	-28	-18	-18	N/A
3/31/2020	N/A	-27	-19	-19	N/A
12/31/2019	N/A	-28	N/A	-18	N/A
9/30/2019	N/A	-34	N/A	-18	N/A
6/30/2019	N/A	-32	N/A	-28	N/A
3/31/2019	N/A	-36	N/A	-30	N/A
12/31/2018	N/A	-41	N/A	-30	N/A
9/30/2018	N/A	-37	N/A	-28	N/A
6/30/2018	N/A	-32	N/A	-16	N/A
3/31/2018	N/A	-30	N/A	-13	N/A
12/31/2017	N/A	-24	N/A	-11	N/A
9/30/2017	N/A	-21	N/A	-14	N/A
6/30/2017	N/A	-23	N/A	-16	N/A
3/31/2017	N/A	-20	N/A	-14	N/A
12/31/2016	N/A	-18	N/A	-12	N/A

애널리스트 향후 성장 전망

수입 대 저축률: SLS 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: SLS (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: SLS 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: SLS 의 수익(연간 67.2%)이 US 시장(연간 12.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: SLS 의 수익(연간 67.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SLS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/05 00:52
종가	2026/07/02 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

SELLAS Life Sciences Group, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
James Molloy	Alliance Global Partners
Aydin Huseynov	Ladenburg Thalmann & Company
Jason McCarthy	Maxim Group

SELLAS Life Sciences Group 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

No longer forecast to breakeven

Forecast to breakeven in 2028

No longer forecast to breakeven

Price target decreased by 17% to US$5.83

Consensus EPS estimates fall by 19%

Consensus EPS estimates upgraded to US$0.87 loss

Recent updates

Why Sellas Remains A Strong Sell After Doubling In Price

New major risk - Share price stability

Sellas Life Sciences Updates Executive Contracts as Key Phase 3 AML Data Nears

SELLAS Life Sciences Group Stock Gains Flexibility As Shareholders Approve Equity Plan And Board

SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing

SELLAS Life Sciences Faces Arbitration Decision and Awaits Phase 3 GPS Data Readout

No longer forecast to breakeven

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 16, 2026

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Profitability

Sellas Life Sciences Group Announces Preclinical Data On SLS009 In AML

Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

Forecast to breakeven in 2028

New minor risk - Share price stability

Independent Director recently bought US$101k worth of stock

Sellas Life Sciences Announces Presentation of Phase 2 Data of Sls009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory Aml with Mds-Related Changes (Aml-Mr) At the 2025 American Society of Hematology (Ash) Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology (ESMO) Congress 2025

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

SELLAS Life Sciences Group Announces Virtual R&D Day on October 29, 2025, Featuring Updates on GPS and SLS009 Programs

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of GPS in AML Without Modification

Sellas Life Sciences Group, Inc. Meets All Primary Endpoints in Phase 2 Trial of Sls009 in R/R Aml and Receives Fda Guidance to Advance into First-Line Therapy Study

SELLAS Life Sciences Group, Inc. Appoints Linghua Wang to Scientific Advisory Board

New minor risk - Share price stability

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

New minor risk - Profitability

Sellas Life Sciences Group, Inc. Appoints Philip C. Amrein and Alex Kentsis to the Scientific Advisory Board

Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of Sls009 R/R AML

SELLAS Life Sciences Group, Inc. Unveils Breakthrough Preclinical Data Highlighting Efficacy of Sls009 in Tp53 Mutated AML At the 2025 AACR Conference

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 17, 2025

SELLAS Life Sciences Group, Inc. to Present At the 2025 American Society of Clinical Oncology Annual Meeting

SELLAS Life Sciences Group, Inc. Announces Cohort 3 Data from the Ongoing Phase 2 Trial of SLS009

No longer forecast to breakeven

SELLAS Life Sciences Group, Inc. Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $24.998852 million.

New minor risk - Share price stability

Sellas Life Sciences Group, Inc. Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML

SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Price target decreased by 17% to US$5.83

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market